Epidemiology of idiopathic pulmonary fibrosis

Clinical Epidemiology

5, 483

DOI: 10.2147/clep.s54815

Citation Report

#	Article	IF	Citations
1	Mucin 5B Promoter Polymorphism Is Associated with Susceptibility to Interstitial Lung Diseases in Chinese Males. PLoS ONE, 2014, 9, e104919.	1.1	47
2	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. Drug Design, Development and Therapy, 2014, 8, 875.	2.0	25
3	Increasing Global Mortality from Idiopathic Pulmonary Fibrosis in the Twenty-First Century. Annals of the American Thoracic Society, 2014, 11, 1176-1185.	1.5	160
4	Design of the INPULSISâ„¢ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1023-1030.	1.3	82
6	An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulmonary Medicine, 2014, 14, 104.	0.8	59
7	Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2014, 48, 1611-1619.	0.9	14
8	Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis. BMC Medicine, 2015, 13, 191.	2.3	30
9	The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulmonary Medicine, 2015, 15, 155.	0.8	79
10	Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Medicine, 2015, 13, 176.	2.3	38
11	Epigenetics in lung fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 454-462.	1.2	55
12	Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to nonâ€fibrotic disease among preâ€lung transplant patients. Neurogastroenterology and Motility, 2015, 27, 1326-1332.	1.6	33
13	Breakdown of Epithelial Barrier Integrity and Overdrive Activation of Alveolar Epithelial Cells in the Pathogenesis of Acute Respiratory Distress Syndrome and Lung Fibrosis. BioMed Research International, 2015, 2015, 1-12.	0.9	59
14	Therapeutic use of fisetin, curcumin, and mesoporous carbon nanoparticle loaded fisetin in bleomycin-induced idiopathic pulmonary fibrosis. Biomedical Research and Therapy, 2015, 2, .	0.3	6
15	MicroRNAs as potential targets for progressive pulmonary fibrosis. Frontiers in Pharmacology, 2015, 6, 254.	1.6	91
16	Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. European Respiratory Journal, 2015, 46, 795-806.	3.1	638
17	Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2015, 3, 587-597.	0.5	2
18	Telomere-Regulating Genes and the Telomere Interactome in Familial Cancers. Molecular Cancer Research, 2015, 13, 211-222.	1.5	29
19	The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice. Pharmacological Research, 2015, 99, 52-62.	3.1	42

#	Article	IF	Citations
20	Nintedanib in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2015, 9, 121-129.	1.0	57
21	Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1194-1196.	3.1	8
22	Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2015, 9, 411-418.	1.0	35
23	Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clinical Investigation, 2015, 5, 621-632.	0.0	12
24	House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis Epidemiology. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1147-1148.	2.5	5
25	Novel Insights Into TRPM7 Function in Fibrotic Diseases: A Potential Therapeutic Target. Journal of Cellular Physiology, 2015, 230, 1163-1169.	2.0	21
26	Disordered breathing during sleep and exercise in idiopathic pulmonary fibrosis and the role of biomarkers. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 315-323.	0.2	19
27	Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. International Journal of Molecular Sciences, 2016, 17, 356.	1.8	207
28	Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery. Journal of Clinical Medicine, 2016, 5, 82.	1.0	86
29	Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy. PLoS ONE, 2016, 11, e0147072.	1.1	56
30	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0151425.	1.1	223
31	Pulmonary fibrosis in the era of stratified medicine. Thorax, 2016, 71, 1154-1160.	2.7	67
32	An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 711-720.	2.2	6
33	Protective effect of apigenin on bleomycin-induced pulmonary fibrosis in mice by increments of lung antioxidant ability and PPARÎ³ expression. Journal of Functional Foods, 2016, 24, 382-389.	1.6	15
34	Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L940-L954.	1.3	39
35	Mesenchymal stem cells in the treatment of chronic lung disease. Respirology, 2016, 21, 1366-1375.	1.3	52
36	Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Annals of the American Thoracic Society, 2016, 13, 1839-1846.	1.5	71
37	Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L238-L254.	1.3	67

#	Article	IF	Citations
38	Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. BMC Pulmonary Medicine, 2016, 16, 107.	0.8	54
39	TGF-Î²1 Upregulates the Expression of Triggering Receptor Expressed on Myeloid Cells 1 in Murine Lungs. Scientific Reports, 2016, 6, 18946.	1.6	13
40	Idiopathic Lung Fibrosis Model for Drug Discovery. , 2016, , 13-31.		1
41	Wnt/Î²â€catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration. FASEB Journal, 2016, 30, 3271-3284.	0.2	97
42	Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulmonary Medicine, 2016, 16, 2.	0.8	75
43	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1213-1218.	2.5	59
44	UK asbestos imports and mortality due to idiopathic pulmonary fibrosis. Occupational Medicine, 2016, 66, 106-111.	0.8	29
45	Therapeutic advances in idiopathic pulmonary fibrosis. Clinical Medicine, 2016, 16, 42-51.	0.8	16
46	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	5.2	523
47	Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2016, 22, 112-122.	0.7	7
48	Role of thioredoxin nitration in bleomycin-induced pulmonary fibrosis in rats. Canadian Journal of Physiology and Pharmacology, 2016, 94, 59-64.	0.7	2
49	Hospital cost and length of stay in idiopathic pulmonary fibrosis. Journal of Medical Economics, 2017, 20, 518-524.	1.0	25
50	Interstitial lung abnormalities: risk and opportunity. Lancet Respiratory Medicine,the, 2017, 5, 95-96.	5.2	10
51	Role of IL-17A in murine models of COPD airway disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L122-L130.	1.3	45
52	The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2017, 44, 7-15.	1.1	27
53	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	1.2	63
54	Imaging of the Lungs in Organ Donors and its Clinical Relevance. Journal of Thoracic Imaging, 2017, 32, 107-114.	0.8	7
55	Dendritic Cell Trafficking and Function in Rare Lung Diseases. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 393-402.	1.4	20

#	Article	IF	Citations
56	Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L741-L747.	1.3	2
57	Occupational and Environmental Risk Factors for Chronic Fibrosing idiopathic Interstitial Pneumonia in South Korea. Journal of Occupational and Environmental Medicine, 2017, 59, e221-e226.	0.9	11
58	Idiopathic Pulmonary Fibrosis: Stem Cell-Mediated Therapeutic Approach. , 2017, , 511-529.		0
59	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
60	The â€œComplex Restrictiveâ€•Pulmonary Function Pattern. Chest, 2017, 152, 1258-1265.	0.4	22
61	Inhibition of Cell Apoptosis and Amelioration of Pulmonary Fibrosis by Thrombomodulin. American Journal of Pathology, 2017, 187, 2312-2322.	1.9	21
62	Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats. Experimental and Therapeutic Medicine, 2017, 14, 609-615.	0.8	6
63	Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype. Journal of Rheumatology, 2017, 44, 1458-1467.	1.0	76
64	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170057.	3.0	162
65	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in Experimental Medicine and Biology, 2017, 1031, 419-442.	0.8	10
66	Interstitial Lung Disease in India. Results of a Prospective Registry. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 801-813.	2.5	170
67	A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2017, 6, 2.	1.0	78
68	Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases. Molecules, 2017, 22, 139.	1.7	30
69	Long-Term Effects of TCM Yangqing Kangxian Formula on Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulating Nuclear Factor-IºB Signaling. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-16.	0.5	13
70	MOXIBUSTION HAS A POSITIVE EFFECT ON PULMONARY FIBROSIS: AN ALTERNATIVE APPROACH. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 125-129.	0.3	6
71	Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2017, 127, 405-414.	3.9	163
72	Idiopathic pulmonary fibrosis. Nurse Practitioner, 2018, 43, 48-54.	0.2	5
73	Palliative Care in Diffuse Interstitial Lung Disease: Results of a Spanish Survey. Archivos De Bronconeumologia, 2018, 54, 123-127.	0.4	4

#	Article	IF	Citations
74	Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4. Scientific Reports, 2018, 8, 3983.	1.6	30
75	Tannic acid modulates fibroblast proliferation and differentiation in response to proâ€fibrotic stimuli. Journal of Cellular Biochemistry, 2018, 119, 6732-6742.	1.2	19
76	Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets. Matrix Biology, 2018, 71-72, 112-127.	1.5	178
77	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
78	Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001â€“2013. European Respiratory Journal, 2018, 51, 1701603.	3.1	69
79	Cuidados paliativos en la enfermedad pulmonar intersticial difusa: resultados de una encuesta de Ã¡mbito nacional. Archivos De Bronconeumologia, 2018, 54, 123-127.	0.4	8
80	An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2018, 23, 159-172.	1.0	20
81	Interstitielle Lungenerkrankungen: epidemiologische Herausforderungen, Register und Biobanken. Karger Kompass Pneumologie, 2018, 6, 70-75.	0.0	0
82	Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. Journal of Clinical Medicine, 2018, 7, 476.	1.0	51
83	Lowâ€dose administration of bleomycin leads to early alterations in lung mechanics. Experimental Physiology, 2018, 103, 1692-1703.	0.9	22
84	Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease â€“ analysis of institutional and population data. Respiratory Research, 2018, 19, 195.	1.4	49
85	Fighting Liver Fibrosis with Naturally Occurring Antioxidants. Planta Medica, 2018, 84, 1318-1333.	0.7	20
86	Use of animal models in IPF research. Pulmonary Pharmacology and Therapeutics, 2018, 51, 73-78.	1.1	81
87	The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in Physiology, 2018, 9, 180.	1.3	53
88	The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L1-L10.	1.3	28
89	Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L360-L370.	1.3	3
90	Causes of Pulmonary Fibrosis in the Elderly. Medical Sciences (Basel, Switzerland), 2018, 6, 58.	1.3	11
91	Bleomycin-enhanced alternative splicing of fibroblast growth factor receptor 2 induces epithelial to mesenchymal transition in lung fibrosis. Bioscience Reports, 2018, 38, .	1.1	9

#	Article	IF	Citations
92	Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators. Frontiers in Immunology, 2018, 9, 670.	2.2	31
93	Impact of donor chest radiography on clinical outcome after lung transplantation. Acta Radiologica Open, 2018, 7, 205846011878141.	0.3	0
94	Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L59-L65.	1.3	37
95	Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respiratory Medicine,the, 2018, 6, 603-614.	5.2	133
96	Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2019, 8, 1232.	1.0	24
97	The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1084-1085.	2.5	0
98	The Possible Pathogenesis of Idiopathic Pulmonary Fibrosis consideringMUC5B. BioMed Research International, 2019, 2019, 1-12.	0.9	28
99	Evaluation of integrin Î±vÎ²6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nature Communications, 2019, 10, 4673.	5.8	73
100	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax, 2019, 74, 1131-1139.	2.7	43
101	Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung, 2019, 197, 551-558.	1.4	23
102	Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries. Annals of the American Thoracic Society, 2019, 16, 393-396.	1.5	14
103	Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respiratory Research, 2019, 20, 127.	1.4	29
104	Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden. Pulmonary Therapy, 2019, 5, 55-68.	1.1	12
105	P120-catenin regulates pulmonary fibrosis and TGF-Î² induced lung fibroblast differentiation. Life Sciences, 2019, 230, 35-44.	2.0	24
106	Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 103.	1.4	78
107	Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes. American Journal of the Medical Sciences, 2019, 357, 359-369.	0.4	45
108	Genetics of Idiopathic Pulmonary Fibrosis. American Journal of the Medical Sciences, 2019, 357, 379-383.	0.4	16
109	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. Current Treatment Options in Rheumatology, 2019, 5, 127-146.	0.6	0

#	Article	IF	Citations
110	Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2019, 13, 117954841983492.	0.5	8
111	The characterisation of interstitial lungÂdisease multidisciplinary team meetings:ÂaÂglobal study. ERJ Open Research, 2019, 5, 00209-2018.	1.1	49
112	TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis. BMC Pulmonary Medicine, 2019, 19, 31.	0.8	20
113	Longitudinal free-breathing MRI measurement of murine lung physiology in a progressive model of lung fibrosis. Journal of Applied Physiology, 2019, 126, 1138-1149.	1.2	7
114	Oxidative stress induces club cell proliferation and pulmonary fibrosis in Atp8b1 mutant mice. Aging, 2019, 11, 209-229.	1.4	16
115	Translational research in pulmonary fibrosis. Translational Research, 2019, 209, 1-13.	2.2	29
116	The genetics of interstitial lung diseases. European Respiratory Review, 2019, 28, 190053.	3.0	41
117	Objectively Measured Chronic Lung InjuryÂon Chest CT. Chest, 2019, 156, 1149-1159.	0.4	9
118	Caveolin-1â€“derived peptide limits development of pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	5.8	58
119	Heterozygous TERT gene mutation associated with familial idiopathic pulmonary fibrosis. Respiratory Medicine Case Reports, 2019, 26, 118-122.	0.2	7
120	Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 197-237.	0.4	0
121	Prognostic Impact of Mediastinal Lymph Nodes in Interstitial Lung Diseases: Is Environmental Exposure the Offender?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1040-1041.	2.5	3
122	Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019, 40, 554-563.	2.7	746
123	Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NFâ€ºB activation. Aging Cell, 2019, 18, e12858.	3.0	113
124	Targeting metabolic dysregulation for fibrosis therapy. Nature Reviews Drug Discovery, 2020, 19, 57-75.	21.5	246
125	Genetic Determinants of Interstitial Lung Diseases. , 2020, , 405-437.		1
126	IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 157, 1513-1521.	0.4	42
127	Micellar electrokinetic capillary chromatographic determination of pirfenidone and 5-carboxy-pirfenidone by direct injection of plasma from patients receiving treatment for idiopathic pulmonary fibrosis (IPF). Microchemical Journal, 2020, 154, 104536.	2.3	5

#	Article	IF	Citations
128	Occupational exposures and idiopathic pulmonary fibrosis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 103-111.	1.1	10
129	Asbestos Exposure Results in Asbestosis and Usual Interstitial Pneumonia Similar to Other Causes of Pneumoconiosis. , 0, , .		1
130	Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: caseâ€“control study. Thorax, 2020, 75, 864-869.	2.7	48
131	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
132	Sex-Based Differences in Interstitial Lung Disease. American Journal of the Medical Sciences, 2020, 360, 467-473.	0.4	9
133	Structure-based virtual screening to identify novel carnitine acetyltransferase activators. Journal of Molecular Graphics and Modelling, 2020, 100, 107692.	1.3	3
134	Idiopathic Pulmonary Fibrosis: Utilization of Health Services and Out-Of-Pocket Health Expenditures in Greece. Value in Health Regional Issues, 2020, 22, 44-48.	0.5	1
135	COUNTERPOINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? No. Chest, 2020, 157, 1413-1414.	0.4	4
136	Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respiratory Investigation, 2020, 58, 320-335.	0.9	63
137	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 963-967.	1.6	3
138	Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016. Respiratory Research, 2020, 21, 152.	1.4	7
139	Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulmonary Medicine, 2020, 20, 67.	0.8	18
140	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 11.	1.4	42
141	Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cellular and Molecular Life Sciences, 2021, 78, 2031-2057.	2.4	175
142	Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology. Radiotherapy and Oncology, 2021, 155, 269-277.	0.3	19
143	Pharmacological effects of indole alkaloids from Alstonia scholaris (L.) R. Br. on pulmonary fibrosis in vivo. Journal of Ethnopharmacology, 2021, 267, 113506.	2.0	19
144	Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases. , 2021, , 583-608.		0
146	Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis. , 2021, , 287-310.		0

#	Article	IF	Citations
147	Interstitial Lung Abnormalities: What Radiologists Should Know. Korean Journal of Radiology, 2021, 22, 454.	1.5	14
149	Ferulic acid ameliorates the progression of pulmonary fibrosis via inhibition of TGF-Î²/smad signalling. Food and Chemical Toxicology, 2021, 149, 111980.	1.8	25
150	Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. British Journal of Radiology, 2021, 94, 20200947.	1.0	16
151	Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. Journal of Diabetes Research, 2021, 2021, 1-11.	1.0	26
152	Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice, 2022, 35, 853-858.	0.5	4
153	A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin. Journal of Pharmacological and Toxicological Methods, 2021, 109, 107057.	0.3	11
154	Downregulation of exosomal let-7d and miR-16 in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 188.	0.8	12
155	Silibinin alleviates silicaâ€induced pulmonary fibrosis: Potential role in modulating inflammation and epithelialâ€mesenchymal transition. Phytotherapy Research, 2021, 35, 5290-5304.	2.8	10
156	Cellular Senescence in Idiopathic Pulmonary Fibrosis. Current Molecular Biology Reports, 2021, 7, 31-40.	0.8	29
157	Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease. Chest, 2021, 160, 879-889.	0.4	13
158	Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation. Environmental Science and Technology Letters, 2021, 8, 903-910.	3.9	8
159	Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128238.	1.0	2
160	The Genetics of Interstitial Lung Diseases. , 2022, , 96-113.		0
161	Immune dysregulation as a driver of idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2021, 131, .	3.9	114
162	Genetics of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2020, , 71-85.	0.1	1
163	Impact of genetic factors on fibrosing interstitial lung diseases. Incidence and clinical presentation in adults. Presse Medicale, 2020, 49, 104024.	0.8	9
164	Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging. Journal of Cell Biology, 2020, 219, .	2.3	36
166	Wilmsâ€™ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. JCI Insight, 2018, 3, .	2.3	32

#	Article	IF	Citations
167	Pharmacological management. , 0, , 196-217.		1
168	Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis. Medical Science Monitor, 2018, 24, 4146-4153.	0.5	14
169	Lung fibrosis and exposure to wood dusts: Two cases report and review of the literature. Medycyna Pracy, 2015, 66, 739-747.	0.3	10
170	MUC5B and Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2015, 12, S193-S199.	1.5	67
171	The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. Journal of Lung, Pulmonary & Respiratory Research, 2018, 5, .	0.3	14
172	The role of club cell phenoconversion and migration in idiopathic pulmonary fibrosis. Aging, 2016, 8, 3091-3109.	1.4	23
173	The Potential Use of Cannabis in Tissue Fibrosis. Frontiers in Cell and Developmental Biology, 2021, 9, 715380.	1.8	13
174	Protective Effect of ATRA on Bleomycin Induced Lung Fibrosis in Rat. , 2014, 4, .		0
176	Idiopathische Lungenfibrose. , 2016, , 127-141.		0
179	The Cause of Idiopathic Pulmonary Fibrosis: A Hypothesis. Journal of Immunobiology, 2017, 02, .	0.3	1
180	Spatial and temporal variability of idiopathic pulmonary fibrosis cases in Silesian Voivodeship in years 2006â€“2010. International Journal of Occupational Medicine and Environmental Health, 2017, 30, 593-601.	0.6	0
181	Unilateral Pulmonary Fibrosis Due to Absence of Right Pulmonary Artery. Cureus, 2019, 11, e5161.	0.2	0
185	Pulmonary disorders. , 2020, , 325-338.		0
186	The role and importance of the family doctor in the diagnosis of idiopathic pulmonary fibrosis. Medic Ro, 2020, 3, 26.	0.0	0
187	The efficacy of pulmonary rehabilitation in improving the clinical status in idiopathic pulmonary fibrosis. Balneo Research Journal, 2020, , 35-44.	0.4	0
190	The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. Journal of Lung, Pulmonary & Respiratory Research, 2018, 5, .	0.3	18
191	Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis. Journal of Cellular Immunology, 2020, 2, 149-156.	0.8	2
192	Idiopathic pulmonary fibrosis and occupational risk factors. Medicina Del Lavoro, 2019, 110, 407-436.	0.3	6

#	Article	IF	Citations
193	A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis. APL Bioengineering, 2021, 5, 046102.	3.3	4
194	NOVEL NANOPARTICULATE SYSTEMS FOR IDIOPATHIC PULMONARY FIBROSIS: A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 3-11.	0.3	1
195	Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease. Expert Review of Respiratory Medicine, 2022, 16, 235-245.	1.0	2
196	Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biology, 2022, 50, 102226.	3.9	9
197	miRNAs Contained in Extracellular Vesicles Cargo Contribute to the Progression of Idiopathic Pulmonary Fibrosis: An In Vitro Aproach. Cells, 2022, 11, 1112.	1.8	8
198	Review on Idiopathic Pulmonary Fibrosis. Asian Journal of Research in Pharmaceutical Science, 2022, , 42-48.	0.1	0
199	Effects of supplementation of vitamins D, C and E on Idiopathic Pulmonary Fibrosis (IPF): A clinical trial. Clinical Nutrition ESPEN, 2022, 49, 295-300.	0.5	4
200	Contribution of Interleukinâ€4â€“Induced Epithelial Cell Senescence to Glandular Fibrosis in <scp>IgG4â€Related</scp> Sialadenitis. Arthritis and Rheumatology, 2022, 74, 1070-1082.	2.9	7
201	The minor T allele of the MUC5B promoter rs35705950 associated with susceptibility to idiopathic pulmonary fibrosis: a meta-analysis. Scientific Reports, 2021, 11, 24007.	1.6	8
203	Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	2.5	25
205	Pulmonary delivery of a recombinant RAGE antagonist peptide derived from high-mobility group box-1 in a bleomycin-induced pulmonary fibrosis animal model. Journal of Drug Targeting, 2022, , 1-11.	2.1	0
207	Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes. Frontiers in Genetics, 2022, 13, 865052.	1.1	4
208	Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis. Future Journal of Pharmaceutical Sciences, 2022, 8, .	1.1	3
209	Construction and Validation of a Novel Prognostic Signature of Idiopathic Pulmonary Fibrosis by Identifying Subtypes Based on Genes Related to 7-Methylguanosine Modification. Frontiers in Genetics, 0, 13, .	1.1	1
210	An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis. Processes, 2022, 10, 1131.	1.3	3
212	Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Cells, 2022, 11, 2095.	1.8	60
213	Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ, The, 0, , e066354.	3.0	14
214	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis â€“ 2021 update. Full-length version. Respiratory Medicine and Research, 2023, 83, 100948.	0.4	1

#	Article	IF	Citations
215	Nonmalignant respiratory disease mortality in male Colorado Plateau uranium miners, 1960â€“2016. American Journal of Industrial Medicine, 2022, 65, 773-782.	1.0	0
216	Natural polysaccharides as potential anti-fibrotic agents: A review of their progress. Life Sciences, 2022, 308, 120953.	2.0	5
217	Polypharmacology in Clinical Applications: Respiratory Polypharmacology. , 2022, , 271-299.		0
218	Incidence and Progression of Fibrotic Lung Disease in an At-Risk Cohort. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 587-593.	2.5	14
219	A novel gene signature based on the hub genes of COVID-19 predicts the prognosis of idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	1
220	The emerging roles of interstitial macrophages in pulmonary fibrosis: A perspective from scRNA-seq analyses. Frontiers in Immunology, 0, 13, .	2.2	16
221	Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols. Disease-a-Month, 2023, 69, 101484.	0.4	5
222	A Novel 5-Methylcytosine- and Immune-Related Prognostic Signature Is a Potential Marker of Idiopathic Pulmonary Fibrosis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-18.	0.7	1
223	Metabolic reprogramming of pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	6
224	Mapping brain endophenotypes associated with idiopathic pulmonary fibrosis genetic risk. EBioMedicine, 2022, 86, 104356.	2.7	2
225	<scp>Clinâ€STAR</scp> corner: Recent <scp>practiceâ€changing</scp> studies at the interface of pulmonary and critical care medicine and geriatrics. Journal of the American Geriatrics Society, 2023, 71, 705-710.	1.3	0
226	Addressing sex and gender to improve asthma management. Npj Primary Care Respiratory Medicine, 2022, 32, .	1.1	6
227	What role for asbestos in idiopathic pulmonary fibrosis? Findings from the IPF job exposures caseâ€“control study. Occupational and Environmental Medicine, 2023, 80, 97-103.	1.3	4
228	Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe, 2022, 18, 220147.	0.6	4
229	Alveolar macrophages drive lung fibroblast function in cocultures of IPF and normal patient samples. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L507-L520.	1.3	6
230	Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility andÂtolerability. EBioMedicine, 2023, 90, 104481.	2.7	30
231	Inhibitory Effects of 3-Cyclopropylmethoxy-4-(difluoromethoxy) Benzoic Acid on TGF-Î²1-Induced Epithelialâ€“Mesenchymal Transformation of In Vitro and Bleomycin-Induced Pulmonary Fibrosis In Vivo. International Journal of Molecular Sciences, 2023, 24, 6172.	1.8	2
232	Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease. PLoS ONE, 2023, 18, e0283110.	1.1	0

#	Article	IF	Citations
243	Idiopathic Interstitial Pneumonias. , 2023, , 1-44.		0